12 articles for T Kiyoi
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists.
Merck Research Laboratories
Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists.
Schering-Plough Research Institute
Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain.
Merck Research Laboratories
New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.
Nippon Organon K.K.
Studies on selectin blockers. 6. Discovery of homologous fucose sugar unit necessary for E-selectin binding.
Kanebo
Studies on selection blockers. 5. Design, synthesis, and biological profile of sialyl Lewis x mimetics based on modified serine-glutamic acid dipeptides.
Kanebo
Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.
Merck Research Laboratories
Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.
Merck Research Laboratories
Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
Carna Biosciences
New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.
Organon K.K.
Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
Carna Biosciences
